Evidence map›Paper›PMID 29344361›Full record

ArticleBiomarker research2018

Platelet protein biomarker panel for ovarian cancer diagnosis.

Marta Lomnytska, Rui Pinto, Susanne Becker, Ulla Engström, Sonja Gustafsson, Christina Björklund, Markus Templin, Jan Bergstrand, Lei Xu, Jerker Widengren and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarker research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 57 citations in OpenAlex.

  1. Towards liquid biopsy-based analysis of antitumour immunity.Nature reviews. Clinical oncology · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. TEP RNA: a new frontier for early diagnosis of NSCLC.Journal of cancer research and clinical oncology · 2024
    Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Marta Lomnytska1Department of Obstetrics and Gynaecology, Academical Uppsala University Hospital, Uppsala University, SE-751 85 Uppsala, Sweden.ORCID 0000-0003-2773-8446
Rui Pinto4Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, St. Mary's Campus, Norfolk Place, W2 1PG, London, England UK.
Susanne Becker3Department of Oncology and Pathology, Cancer Centre Karolinska, Karolinska Institute, SE-171 76 Stockholm, Sweden.
Ulla Engström5Ludwig Institute for Cancer Research Ltd, Box 595, SE-751 24 Uppsala, Sweden.
Sonja GustafssonNeoProteomics AB, Cancer Centre Karolinska, SE-17176 Stockholm, Sweden.
Christina BjörklundNeoProteomics AB, Cancer Centre Karolinska, SE-17176 Stockholm, Sweden.
Markus Templin7NMI Natural and Medical Sciences Institute at the University of Tübingen, 72770 Reutlingen, Germany.
Jan Bergstrand8Experimental Biomolecular Physics, Department of Applied Physics, Royal Institute of Technology, AlbaNova University Center, SE-106 91 Stockholm, Sweden.
Lei Xu8Experimental Biomolecular Physics, Department of Applied Physics, Royal Institute of Technology, AlbaNova University Center, SE-106 91 Stockholm, Sweden.
Jerker Widengren8Experimental Biomolecular Physics, Department of Applied Physics, Royal Institute of Technology, AlbaNova University Center, SE-106 91 Stockholm, Sweden.
Elisabeth Epstein2Institute of Women's and Children's Health, Karolinska Institute, SE-171 76 Stockholm, Sweden.
Bo Franzén3Department of Oncology and Pathology, Cancer Centre Karolinska, Karolinska Institute, SE-171 76 Stockholm, Sweden.
Gert Auer3Department of Oncology and Pathology, Cancer Centre Karolinska, Karolinska Institute, SE-171 76 Stockholm, Sweden.
Karolinska University Hospital · SEAlbaNova · SEKarolinska Institutet · SEImperial College London · GBLudwig Cancer Research · SENatural and Medical Sciences Institute · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlatelets support cancer growth and spread making platelet proteins candidates in the search for biomarkers.

methodsTwo-dimensional (2D) gel electrophoresis, Partial Least Squares Discriminant Analysis (PLS-DA), Western blot, DigiWest.

resultsPLS-DA of platelet protein expression in 2D gels suggested differences between the International Federation of Gynaecology and Obstetrics (FIGO) stages III-IV of ovarian cancer, compared to benign adnexal lesions with a sensitivity of 96% and a specificity of 88%. A PLS-DA-based model correctly predicted 7 out of 8 cases of FIGO stages I-II of ovarian cancer after verification by western blot. Receiver-operator curve (ROC) analysis indicated a sensitivity of 83% and specificity of 76% at cut-off >0.5 (area under the curve (AUC) = 0.831,

conclusionWe identified a group of platelet protein biomarker candidates that can quantify the differential expression between ovarian cancer cases as compared to benign adnexal lesions.

Indexed as

BiomarkerLiquid biopsyOvarian cancerPlatelet proteome

Identifiers

PMID29344361
PMCPMC5767003
OpenAlexW2784116773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.